This Is MS Multiple Sclerosis Community: Knowledge & Support

Roche Holding AG and Biogen Idec Inc reported data from a mid-stage trial of their experimental multiple sclerosis drug ocrelizumab on Friday that showed one patient died of an inflammatory condition.

Data presented at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) showed that the drug reduced disease activity by a significant amount as measured by the number of brain lesions and relapse rate. But some side effects were greater in the ocrelizumab arm than in the placebo arm.

In May, Roche of Switzerland and Biogen of Cambridge, Massachusetts, said they would discontinue studies of the drug as a treatment for rheumatoid arthritis after a safety monitoring board ruled that the risk outweighed the benefit in the RA population.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1397

_________________
The Multiple Sclerosis Resource Centre

Squiffy's House of Fun - Laughter for Multiple Sclerosis

oh, too risky for those arthritis patients, let's give it to the desperate MS ones...

WHOA! EVERY neurologist better come out against this drug now ... it's now as bad as CCSVI ...

STOP EVERYTHING!

I wonder how they studied anything before god's gift of CCSVI came down from the heavens to show science the platonic state of medical perfection.